Ani Pharmaceuticals (ANIP) Tax Provisions (2012 - 2026)

Ani Pharmaceuticals has disclosed Tax Provisions across 15 years of filings, most recently posting $10.7 million for Q1 2026.

• Tax Provisions for Q1 2026 came in at $10.7 million, up 149.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.9 million (up 466.47% YoY), and the FY2025 annual result was $17.5 million, up 573.01% from the prior year.
• Tax Provisions came in at $10.7 million for Q1 2026 at Ani Pharmaceuticals, up from $4.0 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $10.7 million in Q1 2026 to a low of -$7.3 million in Q3 2024.
• The 5-year median for Tax Provisions is $259500.0 (2023), against an average of $678500.0.
• Across the five-year window, Tax Provisions slumped 57570.0% in 2022 and jumped 881.82% in 2024, its largest moves.
• Ani Pharmaceuticals' Tax Provisions stood at -$1.5 million in 2022, then surged by 86.06% to -$207000.0 in 2023, then plunged by 1585.99% to -$3.5 million in 2024, then jumped by 214.3% to $4.0 million in 2025, then jumped by 168.96% to $10.7 million in 2026.
• The last three Tax Provisions figures came in at $10.7 million (Q1 2026), $4.0 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.